JP2020523307A - 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト - Google Patents

血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト Download PDF

Info

Publication number
JP2020523307A
JP2020523307A JP2019567306A JP2019567306A JP2020523307A JP 2020523307 A JP2020523307 A JP 2020523307A JP 2019567306 A JP2019567306 A JP 2019567306A JP 2019567306 A JP2019567306 A JP 2019567306A JP 2020523307 A JP2020523307 A JP 2020523307A
Authority
JP
Japan
Prior art keywords
treatment
nvg
vegf antagonist
anterior segment
antibody vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523307A5 (enExample
Inventor
セルジオ・カジミーロ・シルバ・レアル
オリヴァー・ツァイツ
裕司 岩本
裕司 岩本
小林　正人
正人 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of JP2020523307A publication Critical patent/JP2020523307A/ja
Publication of JP2020523307A5 publication Critical patent/JP2020523307A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019567306A 2017-06-14 2018-06-12 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト Pending JP2020523307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17176072.1 2017-06-14
EP17176072 2017-06-14
PCT/EP2018/065464 WO2018229034A1 (en) 2017-06-14 2018-06-12 Non-antibody vegf antagonists for the treatment of neovascular glaucoma

Publications (2)

Publication Number Publication Date
JP2020523307A true JP2020523307A (ja) 2020-08-06
JP2020523307A5 JP2020523307A5 (enExample) 2021-07-26

Family

ID=59070500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567306A Pending JP2020523307A (ja) 2017-06-14 2018-06-12 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト

Country Status (4)

Country Link
US (1) US20210138032A1 (enExample)
JP (1) JP2020523307A (enExample)
TW (1) TW201904610A (enExample)
WO (1) WO2018229034A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252079B8 (en) 2006-04-07 2020-09-09 Aerpio Therapeutics LLC Antibodies that bind human protein tyrosine phosphatase beta (hptp-beta) and uses thereof
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318143T1 (de) 1996-10-25 2006-03-15 Gilead Sciences Inc Gefaesszellen wachstumsfaktor (vegf) nukleinsaureligand-komplexe
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
JP4723140B2 (ja) 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
DK1767546T3 (da) 2004-06-08 2012-04-23 Chengdu Kanghong Biotechnologies Co Ltd Angiogenese-inhiberende kimært protein og dets anvendelse
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
WO2014033184A1 (en) 2012-08-28 2014-03-06 Novartis Ag Use of a vegf antagonist in treating ocular vascular proliferative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEFFREY R SOOHOO: "AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR GLAUCOMA", CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol. VOL:43, NR:9,, JPN5020007614, December 2015 (2015-12-01), AU, pages 803 - 807, ISSN: 0004827691 *
日本眼科学会雑誌、２０１７年３月、第１２１回臨時増刊号、第２２６頁、アブストラクト番号Ｏ２−１９４, JPN6022029350, ISSN: 0004827692 *

Also Published As

Publication number Publication date
TW201904610A (zh) 2019-02-01
US20210138032A1 (en) 2021-05-13
WO2018229034A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
US11071780B2 (en) Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
US20250268983A1 (en) Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
CN103533950A (zh) Vegf拮抗剂在治疗血管生成眼病中的用途
JP2020523307A (ja) 血管新生緑内障を治療するための非抗体ｖｅｇｆアンタゴニスト
US11944663B2 (en) Method for treating angiogenic eye disorders using VEGF antagonists
JP2024519629A (ja) 血管新生性眼疾患の治療のための長期の高用量ｖｅｇｆアンタゴニストレジメン
JP2025111432A (ja) 色素上皮由来因子（ｐｅｄｆ）を使用する疾患の処置のための方法
EP4429693B1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
US20250339491A1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
AU2024272228A1 (en) Annexin a5 protein as a combination therapy with an anti-vegf agent for use in the treatment of macular oedema or retinal vein occlusion
WO2024236190A1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40094966A (en) Use of a vegf antagonist to treat diabetic retinopathy
EA046420B1 (ru) Применение антагониста vegf для лечения ангиогенных глазных заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230227